
Hoth Therapeutics, Inc. – NASDAQ:HOTH
Hoth Therapeutics stock price today
Hoth Therapeutics stock price monthly change
Hoth Therapeutics stock price quarterly change
Hoth Therapeutics stock price yearly change
Hoth Therapeutics key metrics
Market Cap | 5.62M |
Enterprise value | N/A |
P/E | -0.23 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.48 |
PEG ratio | N/A |
EPS | -2.02 |
Revenue | N/A |
EBITDA | -7.39M |
Income | -7.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHoth Therapeutics stock price history
Hoth Therapeutics stock forecast
Hoth Therapeutics financial statements
Jun 2023 | 0 | -1.87M | |
---|---|---|---|
Sep 2023 | 0 | -2.08M | |
Dec 2023 | 59.53K | -1.70M | -2859.13% |
Mar 2024 | 0 | -2.04M |
Mar 2024 | 0 | -2.04M | |
---|---|---|---|
Sep 2025 | 0 | -1.17M | |
Oct 2025 | 0 | -1.18M | |
Dec 2025 | 0 | -1.05M |
Analysts Price target
Financials & Ratios estimates
2023-06-14 | -2.29 | -2.86 |
---|
Jun 2023 | 11917250 | 1.96M | 16.5% |
---|---|---|---|
Sep 2023 | 12086137 | 1.57M | 13.06% |
Dec 2023 | 9520278 | 704.98K | 7.41% |
Mar 2024 | 8491329 | 658.73K | 7.76% |
Jun 2023 | -1.44M | 0 | 0 |
---|---|---|---|
Sep 2023 | -1.63M | 0 | 2.40M |
Dec 2023 | -3.07M | -1 | 0 |
Mar 2024 | -1.72M | 0 | 0 |
Hoth Therapeutics alternative data
Aug 2023 | 2 |
---|---|
Sep 2023 | 2 |
Oct 2023 | 2 |
Nov 2023 | 2 |
Dec 2023 | 2 |
Jan 2024 | 2 |
Feb 2024 | 2 |
Mar 2024 | 2 |
Apr 2024 | 2 |
May 2024 | 2 |
Jun 2024 | 2 |
Jul 2024 | 2 |
Hoth Therapeutics other data
Period | Buy | Sel |
---|---|---|
Sep 2022 | 20000 | 0 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Purchase | KNIE ROBB director, officer.. | Common Stock | 10,000 | $0.39 | $3,900 | ||
Purchase | KNIE ROBB director, officer.. | Common Stock | 10,000 | $0.4 | $4,000 | ||
Sale | HAYES ANTHONY 10 percent owner | Common Stock, par value $0.0001 | 400,000 | $0.63 | $250,000 | ||
Sale | AIKIDO PHARMA INC. | Common Stock | 400,000 | N/A | N/A | ||
Sale | HAYES ANTHONY 10 percent owner | Common Stock, par value $0.0001 | 400,000 | N/A | N/A | ||
Purchase | SPHERIX INC 10 percent owner | Common Stock | 35,714 | N/A | N/A | ||
Purchase | SPHERIX INC 10 percent owner | Common Stock | 1,700,000 | N/A | N/A |
Insider | Compensation |
---|---|
Mr. Robb Knie (1969) Pres, Chief Executive Officer & Chairman | $525,000 |
Ms. Jane H. Springer (1985) Vice President of Operations | $215,000 |
-
What's the price of Hoth Therapeutics stock today?
One share of Hoth Therapeutics stock can currently be purchased for approximately $1.27.
-
When is Hoth Therapeutics's next earnings date?
Unfortunately, Hoth Therapeutics's (HOTH) next earnings date is currently unknown.
-
Does Hoth Therapeutics pay dividends?
No, Hoth Therapeutics does not pay dividends.
-
How much money does Hoth Therapeutics make?
Hoth Therapeutics has a market capitalization of 5.62M. Hoth Therapeutics made a loss 7.85M US dollars in net income (profit) last year or -$2.86 on an earnings per share basis.
-
What is Hoth Therapeutics's stock symbol?
Hoth Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HOTH".
-
What is Hoth Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Hoth Therapeutics?
Shares of Hoth Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Hoth Therapeutics's key executives?
Hoth Therapeutics's management team includes the following people:
- Mr. Robb Knie Pres, Chief Executive Officer & Chairman(age: 56, pay: $525,000)
- Ms. Jane H. Springer Vice President of Operations(age: 40, pay: $215,000)
-
How many employees does Hoth Therapeutics have?
As Jul 2024, Hoth Therapeutics employs 2 workers.
-
When Hoth Therapeutics went public?
Hoth Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 15 Feb 2019.
-
What is Hoth Therapeutics's official website?
The official website for Hoth Therapeutics is hoththerapeutics.com.
-
Where are Hoth Therapeutics's headquarters?
Hoth Therapeutics is headquartered at 1 Rockefeller Plaza, New York, NY.
-
How can i contact Hoth Therapeutics?
Hoth Therapeutics's mailing address is 1 Rockefeller Plaza, New York, NY and company can be reached via phone at +64 6 756 2997.
Hoth Therapeutics company profile:

Hoth Therapeutics, Inc.
hoththerapeutics.comNASDAQ
2
Biotechnology
Healthcare
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
New York, NY 10020
CIK: 0001711786
ISIN: US44148G2049
CUSIP: 44148G105